Healthcare Services

Increasing Adoption Of Increase In Clinical Research And Development Efforts Fueling The Growth Of The Market Due To Advancements In Diagnostics And Treatment Options Is Influencing The Malignant Mesothelioma Market

June 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Value Expansion Is Expected For The Malignant Mesothelioma Market Over The Forecast Period?

The market size for malignant mesothelioma has seen strong expansion in recent years. It is forecast to increase from $2.61 billion in 2025 to $2.77 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.3%. The growth observed historically is attributable to factors such as past asbestos exposure in construction and manufacturing, the prolonged latency period of the disease, restricted early treatment alternatives, increasing awareness of occupational health, and steady improvements in diagnostic imaging.

The malignant mesothelioma market is set for robust expansion in the coming years, with projections indicating a rise to $3.53 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.3%. This growth during the forecast period is primarily fueled by advancements in immunotherapy and targeted drugs, increased investment in rare cancer research, an escalating number of clinical trials, refined diagnostic technologies, and higher healthcare spending on oncology. Notable trends for the forecast period include a wider adoption of immunotherapy and targeted therapies, a heightened focus on multimodal treatment strategies, a greater demand for early and accurate diagnosis, the expansion of specialized mesothelioma treatment centers, and increased participation in clinical trials for rare cancers.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22046&type=smp

What Primary Factors Are Fueling The Expansion Of The Malignant Mesothelioma Market?

The expansion of the malignant mesothelioma market is anticipated to be fueled by growing clinical research and development endeavors. These R&D efforts encompass conducting scientific investigations and trials focused on creating new drugs, treatments, and medical devices. Such initiatives involve assessing the safety, efficacy, and potential side effects of novel products through controlled clinical trials. The surge in clinical research and development efforts stems from an increasing demand for enhanced and new treatments, especially given the rising incidence of chronic diseases and complex health conditions. Research and development actively propels the malignant mesothelioma sector by accelerating advancements in diagnostics, therapies, and targeted treatments, thereby fostering innovative methods to improve early detection, boost survival rates, and formulate more effective, less invasive treatment options. For instance, in January 2025, according to Anadolu Agency, a Turkey-based state-run news agency, clinical trials constitute nearly 40% of the U.S. pharmaceutical research budget, totaling approximately $7 billion annually. Consequently, the escalating research and development efforts are a significant factor driving the growth of the malignant mesothelioma market.

How Is The Malignant Mesothelioma Market Distributed Across Key Segments?

The malignant mesothelioma market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Radiation Therapy, Surgery, Immunotherapy, Targeted Therapy

2) By Route Of Administration: Oral, Intravenous, Injectable

3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies

4) By End-User: Hospitals, Oncology Clinics

Subsegments:

1) By Chemotherapy: Alkylating Agents, Antimetabolites, Combination Therapy

2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), Stereotactic Body Radiation Therapy (SBRT), Proton Therapy

3) By Surgery: Pleurectomy Or Decortication (P/D), Extrapleural Pneumonectomy (EPP), Cytoreductive Surgery, Palliative Surgery

4) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Tumor Vaccines, Adoptive Cell Therapy

5) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Angiogenesis Inhibitors, Mesothelin-Targeted Agents, Gene Therapy-Based Approaches

Which Trends Are Influencing The Direction Of The Malignant Mesothelioma Market?

Major companies operating in the malignant mesothelioma market are concentrating on developing advanced treatment options, such as monoclonal antibody treatments, to suppress tumor growth and improve treatment accuracy. Monoclonal antibodies refer to laboratory-produced proteins that mimic the immune system’s ability to detect and target specific antigens, like those found on cancer cells. For instance, in November 2023, Ono Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, received supplemental approval in Japan for the expanded use of Opdivo (nivolumab), a human anti-human PD-1 monoclonal antibody for the treatment of malignant mesothelioma (excluding malignant pleural mesothelioma). This approval designates Opdivo as a new treatment option for this condition, where no standard treatments were previously available. Opdivo was designated an orphan drug for this indication, highlighting its potential to address a significant medical need.

Who Are The Leading Firms Participating In The Malignant Mesothelioma Market?

Major companies operating in the malignant mesothelioma market are AstraZeneca PLC, Bristol Myers Squibb Company, Merck & Co. Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Gilead Sciences Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Bayer AG, Eisai Co. Ltd., Astellas Pharma Inc., Ono Pharmaceutical Co. Ltd., PharmaMar S.A.

Access The Complete Malignant Mesothelioma Market Report:

https://www.thebusinessresearchcompany.com/report/malignant-mesothelioma-global-market-report

Which Area Represents The Largest Portion Of The Malignant Mesothelioma Market?

North America was the largest region in the malignant mesothelioma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant mesothelioma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Malignant Mesothelioma Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=22046&type=smp

Browse Through More Reports Similar to the Global Malignant Mesothelioma Market 2026, By The Business Research Company

Melanoma Therapeutics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/melanoma-therapeutics-global-market-report

Metastatic Melanoma Therapeutics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/metastatic-melanoma-therapeutics-global-market-report

Melanoma Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/melanoma-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795